Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METRIC: CDX-011 vs Capecitabine in Metastatic gpNMB+ TNBC
NCT01997333Phase 2Completed
- Sponsor
- Celldex Therapeutics
- Start
- Nov 2013
- Primary completion
- Nov 2017
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of glembatumumab vedotin in triple-negative breast cancer (TNBC) (2 arms), sponsored by Celldex Therapeutics. Primary endpoint: Progression Free Survival. Started Nov 2013; status: completed.
02
Drugs
glembatumumab vedotin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01997333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01997333.